Crossmark

Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators

Crossref DOI link: https://doi.org/10.1186/s12885-018-4556-6

Published Online: 2018-06-20

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Inoue, Kenichi http://orcid.org/0000-0003-2686-8732
Ninomiya, Jun

Saito, Tsuyoshi

Kimizuka, Kei

Kurosumi, Masafumi
Funding

Funding for this research was provided by:

National Cancer Center Research and Development Fund (23-A-16, 23-A-17, 26-A-4)

Research for Innovative Treatment of Cancer from the Ministry of Health, Labour and Welfare (H26-applied-general-043,046)

Japan Agency for Medical Research and Development (15ck0106046h0002, 15ck0106049h0002)
License Information

Text and Data Mining valid from 2018-06-20

Version of Record valid from 2018-06-20
More Information

Article History

Received: 1 November 2017

Accepted: 25 May 2018

First Online: 20 June 2018

Ethics approval and consent to participate

: All patients provided written informed consent before enrollment. The data were used only for research. The study protocol was approved by the following ethics bodies: for Saitama Cancer Institutional Review Board; for Ninomiya Hospital, Central Ethics Committee at Saitama Cancer Center; for Japanese Red Cross Saitama Hospital, Ethics Committee; and for Kasukabe Medical Center, Ethics Committee.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below